Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536

ABSTRACT

Introduction: TIGIT is an inhibitory receptor expressed by lymphocytes that suppresses the immune response against tumor cells. There is a great need to discover and develop new therapies focused on inhibiting the action of TIGIT and consequently improving the immune response in the various types of cancer. Authors of WO2018102536 patent propose a method to eradicate cancer utilizes anti-TIGIT antibody, etigilimab, in combination with anti-PD-1/PD-L1 antibody, nivolumab.

Areas covered: WO2018102536 patent describes a method of cancer combinatorial treatment consisting of the utilization of either a pharmaceutical cocktail containing anti-TIGIT and an anti-PD-L1 antibody.

Expert opinion: The results of the clinical trials only support trials regarding the tolerability of therapy with etigilimab, but does not show data related to the combined use of etigilimab and nivolumab.

KEYWORDS:

• TIGIT
• PD-1
• cancer
• immunotherapy
• patent
• combination therapy

Acknowledgments

The authors thank the Mexican people for the support, through their taxes, provided for the development of this article.

Authors’ contributions

M Perez-Santos designed the study, obtained data of antibodies patent and drafted the paper; M Anaya-Ruiz designed the study, analyzed state art of patent and drafted the paper; I Herrera-Camacho analyzed chemistry conditions of antibodies; NH Rosas-Murrieta and L Millán-Pérez Peña analyzed biological conditions of antibodies.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.